PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00809016 |
Recruitment Status
:
Completed
First Posted
: December 16, 2008
Last Update Posted
: May 13, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Imaging procedures, such as PET scans, may determine the extent of cancer and help doctors plan radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy that uses a 3-dimensional image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This clinical trial is studying PET scans to see how well they work in patients with head and neck cancer who are undergoing 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer | Radiation: 3-dimensional conformal radiation therapy Radiation: fludeoxyglucose F 18 Radiation: intensity-modulated radiation therapy | Not Applicable |
OBJECTIVES:
Primary
- To assess the value of pre-treatment PET in determining the target volume in patients with head and neck cancer undergoing three-dimensional conformational radiotherapy and intensity-modulated radiotherapy.
Secondary
- To evaluate variations in weekly fludeoxyglucose F 18 PET imaging during the first 5 weeks of treatment.
- To determine the relationship between changes in tumor metabolism during radiotherapy and control tumor at 3 months and at 1 year post-treatment.
OUTLINE: This is a multicenter study.
Patients undergo fludeoxyglucose F18 PET (FDG-PET) in addition to conventional imaging at baseline. Patients undergo standard three-dimensional conformational radiotherapy and intensity-modulated radiation therapy 5 days a week for 5 weeks.
Some patients also undergo weekly FDG-PET during treatment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Non-Randomized |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors |
Study Start Date : | May 2007 |
Actual Primary Completion Date : | May 2011 |

- Difference between the target volume to be irradiated as measured by conventional imagining and PET

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed head and neck cancer
- No nasopharyngeal or paranasal sinus cancer
- Locally advanced disease (T3 or T4)
- Not in complete remission
- Planning to undergo curative radiotherapy (minimum dose of 66 Gy), with or without standard treatment (i.e., platinum-based chemotherapy or biological therapy/rituximab)
- Measurable tumor according to RECIST criteria
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Not pregnant or nursing
- Able to lie still for 1 hour
- No history of progressive neoplastic disease
- No known hypersensitivity to fludeoxyglucose F18 or any of its excipients
-
No severe or uncontrolled systemic disease, including any of the following:
- Kidney disease
- Liver disease
- Cardiac disease
- Unstable or uncompensated respiration
- Uncontrolled diabetes (i.e., glucose ≥ 1.5 g/L)
- No geographical, social, or psychological conditions that make follow-up impossible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior surgery
- No concurrent experimental agents

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809016
France | |
Centre Oscar Lambret | |
Lille, France, 59020 |
OverallOfficial: | Eric Lartigau, MD, PhD | Centre Oscar Lambret |
ClinicalTrials.gov Identifier: | NCT00809016 History of Changes |
Other Study ID Numbers: |
CDR0000626776 COL-0606 COL-TEPORL COL-RCB 2007-A00291-52 INCA-RECF0488 |
First Posted: | December 16, 2008 Key Record Dates |
Last Update Posted: | May 13, 2011 |
Last Verified: | July 2009 |
Keywords provided by National Cancer Institute (NCI):
salivary gland acinic cell tumor recurrent squamous cell carcinoma of the hypopharynx stage III squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the hypopharynx recurrent squamous cell carcinoma of the larynx stage III squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the larynx recurrent verrucous carcinoma of the larynx stage III verrucous carcinoma of the larynx stage IV verrucous carcinoma of the larynx recurrent adenoid cystic carcinoma of the oral cavity recurrent mucoepidermoid carcinoma of the oral cavity recurrent verrucous carcinoma of the oral cavity stage III adenoid cystic carcinoma of the oral cavity stage III mucoepidermoid carcinoma of the oral cavity |
stage III verrucous carcinoma of the oral cavity stage IV adenoid cystic carcinoma of the oral cavity stage IV mucoepidermoid carcinoma of the oral cavity stage IV verrucous carcinoma of the oral cavity recurrent basal cell carcinoma of the lip recurrent squamous cell carcinoma of the lip and oral cavity stage III basal cell carcinoma of the lip stage III squamous cell carcinoma of the lip and oral cavity stage IV basal cell carcinoma of the lip stage IV squamous cell carcinoma of the lip and oral cavity metastatic squamous neck cancer with occult primary squamous cell carcinoma recurrent metastatic squamous neck cancer with occult primary untreated metastatic squamous neck cancer with occult primary recurrent lymphoepithelioma of the oropharynx recurrent squamous cell carcinoma of the oropharynx |
Additional relevant MeSH terms:
Head and Neck Neoplasms Neoplasms by Site Neoplasms |
Fluorodeoxyglucose F18 Radiopharmaceuticals Molecular Mechanisms of Pharmacological Action |